Clinical trial NCT04847739: Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)
Official title: Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Perianal Fistula
Crohn's Disease
Keywords: Matrix plug
Mesenchymal stem cells
Fistula plug
Refractory
Recurrent
STOMP
Autologous
Lead sponsor: Avobis Bio, LLC
Sponsor class: INDUSTRY
Collaborators: name: Alimentiv Inc.
First posted: 2021-04-19
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Phase II study to assess the safety and efficacy of AVB-114 in treatment of complex Crohn's perianal fistulas in subjects with quiescent rectal disease and whose fistula has failed to respond to biologic or conventional therapy. Combined remission of treated perianal fistula in the investigational treatment arm will be compared to a standard of care control arm.

The study has 2 parts:

Part 1: All required study visits for subjects who initially receive study treatment and those who receive standard of care therapy (control arm).

Part 2: Subjects who are enrolled in the control arm may receive treatment with AVB-114 following week 36. Those subjects then will be followed as specified in the clinical protocol.

Detailed description: AVB-114 is an investigational therapy which offers a new therapeutic approach to treating this unmet medical need. The drug product is a mesenchymal cell substrate system comprised of autologous mesenchymal cells incubated with a 3-dimensional bioabsorbable substrate. The drug substance is expanded, pure mesenchymal stem cells (MSC) which are known to modulate local inflammation and orchestrate tissue healing. By incubating cells with a 3-dimensional bioabsorbable substrate designed for anal fistula geometry, cells are locally delivered into the fistula tract to promote healing.

Eligibility criteria: Inclusion Criteria:

1. Provision of signed and dated ICF.
2. Ability and willingness to comply with study protocol and study requirements for the duration of the study.
3. Male or female, 18-70 years of age
4. Subjects with CD diagnosed at least 6 months prior to screening visit.
5. Subjects with a single fistula tract with one internal opening and one external opening.
6. Subjects whose perianal fistula(s) were previously treated with either biologic or conventional therapy whose fistula has demonstrated a failed response or who have documented medication intolerance.
7. Women of childbearing potential (WCBP) must have negative serum pregnancy test at screening (sensitive to 25 IU human chorionic gonadotropin). WCBP participating in this study must agree to use an adequate method of contraception during the entire duration of the study. Males who have sexual partners that are women of childbearing potential must be willing to use a barrier method for contraception for the duration of study.

Exclusion Criteria:

1. Clinically significant medical conditions within the six months before screening that would, in the opinion of the investigator, compromise the safety of the subject with study participation and/or the ability of the subject to follow study protocol.
2. Evidence of hepatitis B, C, or HIV or subjects with congenital or acquired immunodeficiencies.
3. Participation in an investigational drug study (within 30 days of last administration from screening visit) or investigational medical device study (within 1 year of implant from screening visit) where investigational treatment (drug or device) is placed in rectum, vagina, or near fistula location, or that may potentially interact with study treatment.
4. History (within previous 5 years of screening visit) of invasive cancer including melanoma (with the exception of localized skin cancers).
5. Subjects pregnant, trying to become pregnant, or are breast feeding.
6. Subjects with known allergies or hypersensitivity to aminoglycosides and contraindications to Magnetic Resonance (MR) evaluations and/or to MR contrast.
7. History of clinically significant fat-directed autoimmunity.
8. Genito-urinary fistulization, including rectovaginal (i.e., fistulae that transverse the vaginal canal).
9. Presence of an ileal anal pouch.
10. Active, unresolved infection requiring parenteral antibiotics.
11. Any major surgery of the gastrointestinal tract (including one or more segments of the colon or terminal ileum) within 3 months prior to screening visit. Presence of stoma is not exclusionary.
12. Subjects who had a definitive surgical procedure for the target fistula or a perianal procedure that resulted in a large soft tissue defect within 6 months prior to screening visit.
13. Subjects where the target adipose collection harvest site is compromised due to a previous cool sculpting procedure, local radiation, chemotherapy, recent tattoos, local infection, or other reasons that may compromise the adipose tissue for study use.
14. Subjects previously treated with Cx601/Alofisel or other allogeneic or autologous stem-cell therapy within the past 6 months.
15. Contraindications to the anesthetic procedure (local and general) or to the adipose tissue collection procedure.
16. Subjects with one or more of the following fistula types or anatomic presentations:

    1. Horseshoe fistulas
    2. Fistulas that do not have an opening inside the anal canal or low rectum
    3. Blind ending sinus tracts (no external opening)
    4. Branching fistulas. A previously performed conversion of a branching fistula tract to a single tract is not exclusionary
    5. \>1 internal opening
    6. Moderate or severe proctitis
    7. Severe rectal mucosal fibrosis surrounding the internal opening preventing the securing of the fistula plug cap.
    8. Any anatomical limitation to successfully securing the fistula plug cap
17. Evidence by colonoscopy of moderately or greater active luminal CD.
18. Subject with ongoing systemic or rectal steroids for CD in the last 2 weeks prior to screening and baseline study visits.
19. History of, or concurrent high-grade dysplasia, adenocarcinoma, and carcinoma in situ on colonoscopy within 5 years of screening visit.
20. Subjects with renal insufficiency (creatinine value \> 1.8 mg/dL, eGFR \< 44, or patient undergoing dialysis).
21. Subjects with a hemoglobin less than 8 gm/dL.
22. Subjects with serum aspartate transaminase (AST) or alanine transaminase (ALT) \> 2 times the upper limit of normal (ULN).
23. Subjects with an abscess within the fistula tract that cannot be resolved prior to treatment.
24. Subjects with known coagulopathy (abnormal INR) or thrombocytopenia as indicated by a platelet count \< 75,000.
25. Subjects with history of substance abuse (drug or alcohol) that would interfere with the ability to comply with the study protocol and study requirements.

Primary outcomes:
measure: Change in proportions of subjects with combined remission of treated perianal fistula between the AVB-114 and standard of care groups.
timeFrame: 36 weeks
Secondary outcomes:
measure: Change in proportions of subjects with fistula clinical remission between the AVB-114 and standard of care groups.
timeFrame: Week 12 to Week 104
measure: Change in the means of durability of clinical remission between the AVB-114 and standard of care groups.
timeFrame: Week 12 to Week 104
measure: Change in means of time to clinical remission between the AVB-114 and standard of care groups.
timeFrame: Week 12 to Week 104
measure: Change in proportions of subjects with fistula relapse between the AVB-114 and standard of care groups.
timeFrame: Week 12 to Week 104
measure: Change in means of time to fistula relapse between the AVB-114 and standard of care groups.
timeFrame: Week 12 to Week 104
measure: Change in proportions of radiologic response of treated fistula between the AVB-114 and standard of care groups.
timeFrame: Baseline, Week 12 to Week 52
measure: Change in means of disease activity index scores using the Perianal Disease Activity Index (PDAI) between the AVB-114 and standard of care groups.
timeFrame: Baseline, Week 36
measure: Change in means of disease activity index scores using the short Crohn's Disease Activity Index (sCDAI) between the AVB-114 and standard of care groups.
timeFrame: Baseline, Week 36
measure: Change in means of patient quality of life assessment scores using the Euroqol 5 Diumention 5, level measure of health status (Eq-5Q-5L) between the AVB-114 and standard of care groups.
timeFrame: Baseline, Week 36
measure: Change in means of patient quality of life assessment scores using the Inflammatory Bowel Disease Questionnaire (IBDQ) between the AVB-114 and standard of care groups.
timeFrame: Baseline, Week 36
measure: Change in patient assessment of impact to daily functionality related to treated fistula between the AVB-114 and standard of care groups.
timeFrame: Baseline, Week 12 to Week 36
measure: Change in the evaluations of patient care trajectory related to treated fistula between the AVB-114 and standard of care groups.
timeFrame: Week 12 to Week 36
measure: Change in number of adverse events between the AVB-114 and standard of care groups.
timeFrame: Day 1 to Week 104
measure: Change in number of serious adverse events between the AVB-114 and standard of care groups.
timeFrame: Day 1 to Week 104
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Mayo Clinic Arizona
state: Arizona
city: Los Angeles
country: United States
facility: Office of Phillip Fleshner, MD
state: California
city: Redwood City
country: United States
facility: Stanford University
state: California
city: Sacramento
country: United States
facility: UC Davis
state: California
city: Aurora
country: United States
facility: University of Colorado School of Medicine
state: Colorado
city: Jacksonville
country: United States
facility: Mayo Clinic Jacksonville
state: Florida
city: Miami
country: United States
facility: University of Miami
state: Florida
city: Chicago
country: United States
facility: UChicago Medicine and Biological Sciences
state: Illinois
city: Indianapolis
country: United States
facility: Indiana University Health University Hospital
state: Indiana
city: Boston
country: United States
facility: Mass Gen Hospital
state: Massachusetts
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: New York
country: United States
facility: NYU Langone Health
state: New York
city: New York
country: United States
facility: Weill Cornell Medical College - NY Presbyterian Hospital
state: New York
city: Cincinnati
country: United States
facility: University of Cincinnati
state: Ohio
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Alimentiv Inc.
name: Joan Morris
role: STUDY_DIRECTOR
References: